IMARC Group, a leading market research company, has recently releases report titled “Antipsychotic Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2032,” The study provides a detailed analysis of the industry, including the global antipsychotic drugs market share, size, trends, and growth forecast. The report also includes competitor and regional analysis and highlights the latest advancements in the market.
Report Highlights:
How big is the antipsychotic drugs market?
The global antipsychotic drugs market size reached US$ 16.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 28.2 Billion by 2032, exhibiting a growth rate (CAGR) of 6.2% during 2024-2032.
Factors Affecting the Growth of the Antipsychotic Drugs Industry:
- Increasing prevalence of psychiatric disorders:
One of the primary factors driving the antipsychotic drugs market is the rising prevalence of psychiatric disorders, such as schizophrenia, bipolar disorder, and major depressive disorder. These disorders are characterized by disturbances in mood, thinking, and behavior, leading to significant impairment in daily functioning. With growing awareness and improved diagnostic techniques, more individuals are seeking treatment for these conditions, thereby increasing the demand for antipsychotic drugs. Moreover, factors such as urbanization, changing lifestyles, and increasing stress levels are contributing to the escalating incidence of psychiatric disorders, further propelling the demand for antipsychotic medications.
- Technological advancements and drug innovation:
Another crucial factor driving the antipsychotic drugs market is the continuous advancements in pharmaceutical research and development (R&D). Pharmaceutical companies are investing heavily in developing innovative antipsychotic medications with improved efficacy, safety profiles, and modes of administration. These advancements include the development of novel drug delivery systems, such as long-acting injectables and implantable devices, which enhance patient compliance and treatment outcomes. Furthermore, breakthroughs in neuroscience have identified specific neurotransmitter systems and neural circuits implicated in schizophrenia and other psychotic disorders, allowing the development of targeted therapies, which is further aiding in market expansion.
- Aging population and increasing healthcare expenditure:
As the global population continues to age, the prevalence of age-related psychiatric conditions, such as dementia and delirium, is expected to rise. Elderly individuals are particularly vulnerable to these disorders due to age-related neurodegenerative changes and comorbid medical conditions. Moreover, increasing healthcare expenditure, particularly in emerging economies, is fueling the demand for antipsychotic drugs. Besides this, governments and healthcare organizations are allocating resources to improve mental healthcare infrastructure, enhance access to treatment, and raise awareness about psychiatric disorders. This increased investment in mental health services, coupled with rising disposable incomes and expanding insurance coverage, is impelling the market growth.
Request for a sample copy of this report: https://www.imarcgroup.com/antipsychotic-drugs-market/requestsample
Antipsychotic Drugs Market Report Segmentation:
Breakup By Therapeutic Class:
- First Generation
- Haldol
- Navane
- Others
- Second Generation
- Invega
- Latuda
- Seroquel
- Risperdal
- Zyprexa
- Geodon
- Others
- Third Generation
- Abilify
Second-generation antipsychotic drugs dominate the market due to superior efficacy and reduced side effects compared to first-generation counterparts.
Breakup By Application:
- Schizophrenia
- Bipolar Disorder
- Unipolar Depression
- Dementia
- Others
Schizophrenia holds the majority of the market share due to its high prevalence and the effectiveness of antipsychotic medications in managing its symptoms.
Breakup By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Retail pharmacies represent the largest market segment owing to their widespread accessibility and convenience for patients seeking prescription medications.
Breakup By Region:
- North America (United States, Canada)
- Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa
North America emerges as the leading market due to high healthcare spending, advanced healthcare infrastructure, and significant prevalence of psychiatric disorders in the region.
Global Antipsychotic Drugs Market Trends:
The expanding understanding of the role of inflammation and immune dysregulation in psychiatric disorders, alongside the development of immunomodulatory antipsychotic medications, is bolstering the market growth. Concurrent with this, the increasing demand for personalized medicine and pharmacogenomics in psychiatric treatment based on individual genetic profiles to enhance treatment efficacy, reduce adverse effects, and foster patient adherence is acting as another significant growth-inducing factor. Furthermore, the emergence of digital therapeutics and telepsychiatry platforms offering remote access to mental health services, including medication management and therapy sessions, is propelling the market forward.
Who are the key players operating in the industry?
The report covers the major market players including:
- AbbVie Inc.
- Alkermes plc
- Dr. Reddy’s Laboratories Ltd.
- Johnson & Johnson
- Otsuka Pharmaceutical Co. Ltd.
- Viatris Inc.
Browse the full report with TOC and list of Figures: https://www.imarcgroup.com/antipsychotic-drugs-market
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact US:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
USA: +1-631-791-1145 | Asia: +91-120-433-0800
Email: sales@imarcgroup.com
LinkedIn: https://www.linkedin.com/company/imarc-group/mycompany/
